Market revenue in 2023 | USD 118.8 million |
Market revenue in 2030 | USD 209.6 million |
Growth rate | 8.4% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Roche Holding AG ADR, Qiagen NV, Siemens Healthineers AG ADR, Becton Dickinson & Co, Illumina Inc, Epigenomics AG, Koninklijke Philips NV, FUJIFILM Holdings Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.36% in 2023. Horizon Databook has segmented the India liver cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Rise in prevalence of non-alcoholic fatty liver disease (NAFLD) is a one of the major factors anticipated to fuel market growth in the near future. A research study was conducted by the Indian Journal of Medical Research in April 2019, which was aimed at studying NAFLD causing HCC. The study states that the prevalence of non-alcoholic fatty liver disease varies due to variations in the ethnicity, lifestyle as well as the criteria used for diagnosis.
In the West the prevalence of NASH and NAFLD has been estimated to be around 3-4 & 10-24 per cent, respectively. Whereas, in India, the prevalence of nonalcoholic fatty liver disease ranges from about 9 to 32 per cent. Lower prevalence is mostly observed in the rural community, whereas higher prevalence was observed in urban areas.
Horizon Databook provides a detailed overview of country-level data and insights on the India liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into India liver cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account